Chapter 1. Report Scope & Research Methodology
1.1 Market Segmentation
1.1.1 Segment Definition
1.1.1.1 Product Type
1.1.1.2 Type
1.2 Estimates and Forecast Timeline
1.3 Research Methodology
1.3.1 Information Procurement
1.3.2 Purchased Database
1.3.3 Internal Database
1.3.4 Secondary Sources
1.3.5 Primary Research
1.3.6 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Three Pillars of Market Estimation
1.6.1.1 Secondary Market Research
1.6.1.2 Primary Market Intelligence
1.6.1.2.1 In-Depth Interviews (IDIs)
1.6.1.2.2 Online Survey Program
1.6.2 Market Modeling & Forecasting
1.6.2.1 Model 1: Volume-Price Analysis
1.6.2.1.1 Step 1: Prescription volume estimation
1.6.2.1.2 Channel-Wise Methodology
1.6.2.1.2.1 Retail Chains (CVS, Walgreens, etc.)
1.6.2.1.2.2 Supermarket Pharmacies (Kroger, Albertsons, Publix)
1.6.2.1.2.3 Health System / Hospital Outpatient Pharmacies
1.6.2.1.2.4 Independent Pharmacies
1.6.2.1.2.5 Mail-Order Pharmacies
1.6.2.1.2.6 Specialty / Central Fill Pharmacies
1.6.2.1.2.7 Long-Term Care (LTC) and Defense-Related Pharmacies
1.6.2.1.2.8 ePharmacies (Amazon, Capsule, Hims & Hers, etc.)
1.6.2.1.2.9 Other Channels
1.6.2.1.2.10 Aggregation & Triangulation
1.6.2.1.3 Step 2: Determining Average Realized Price (ARP)
1.6.2.1.4 Step 2: OTC Revenue
1.6.2.2 Model 2: Company Market Share Analysis
1.6.2.2.1 Step 1: Public Filings
1.6.2.2.2 Step 2: Private & Independent Estimates
1.6.2.2.3 Step 3: Market Share Allocation
1.6.2.3 CAGR/Forecasting Calculations & Assumptions
1.6.2.3.1 Key Forecasting Drivers and Weights
1.6.2.3.2 Scenario Framework (2025-2033)
1.6.2.3.3 Factor-Based Impact Assessment
1.6.3 Estimation Process: Pharmacy Type Split By Catchment Area
1.6.3.1 Data Sources
1.6.3.2 Estimation Process
1.6.4 Estimation Process: Pharmacy Type Split By Product Form
1.6.5 Company-Level Metric’s Estimation
1.6.5.1 Financial Performance
1.6.5.1.1 2024 Revenue & EBITDA (Pharmacy-Only)
1.6.5.1.2 5-Year Forecast of Revenue & EBITDA
1.6.5.1.3 Balance Sheet Health Indicators
1.6.5.2 Volumes & Operations
1.6.5.2.1 2024 Total Prescriptions; 5-Year Rx Forecast
1.6.5.2.2 % Fulfilled via Central Fill; Volumes Split by Catchment Area
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Research Objectives
1.9.1 Objective - 1
1.9.2 Objective - 2
1.9.3 Objective - 3
Chapter 2. Executive Summary
2.1 Market Snapshot
2.2 Segment Outlook - I
2.3 Segment Outlook- II
2.4 Competitive Scenario
Chapter 3. U.S. Pharmacy Market - Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related Market Outlook
3.1.2.1 U.S. pharmacy benefit management market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing prevalence of chronic diseases
3.2.1.2 Technological advancements
3.2.1.3 Expanding health insurance coverage
3.2.1.4 Increasing demand for specialty drugs
3.2.2 Market Restraint Analysis
3.2.2.1 Product recalls and lawsuits
3.2.2.2 Lack of trained staff
3.2.3 Market Opportunity Analysis
3.2.4 Market Challange Analysis
3.3 Regulatory Scenario & Reimbursement Outlook
3.3.1 Regulatory Scenario
3.3.2 Reimbursement Scenario
3.4 Business Environment Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 Pestle Analysis
Chapter 4. U.S. Pharmacy Market: Product Type Estimates & Trend Analysis
4.1 U.S. Pharmacy Market: Product Type Segment Dashboard
4.2 Product Type Movement & Market Share Analysis, 2024 & 2033
4.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Product Type (USD Billion)
4.3.1 Prescription
4.3.1.1 Prescription market, 2021-2033 (USD Billion)
4.3.2 Over-the-Counter (OTC)
4.3.2.1 OTC market, 2021-2033 (USD Billion)
Chapter 5. U.S. Pharmacy Market: Type Estimates & Trend Analysis
5.1 U.S. Pharmacy Market: Type Segment Dashboard
5.2 Type Movement & Market Share Analysis, 2024 & 2033
5.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Type, 2021-2033 (USD Billion)
5.4 U.S. Pharmacy Market: Estimated Number of Pharmacies, By Type, 2021-2033 (Unit)
5.5 U.S. Pharmacy Market: Estimated Prescription Volume, By Type, 2021-2033 (Million)
5.6 U.S. Pharmacy Market: Estimated Prescription Volume, By Catchment Area, 2024 (%)
5.7 U.S. Pharmacy Market: Estimated Prescription Volume, By Filled Prescriptions (TRx), 2024 (%)
5.7.1 Retail Chains
5.7.1.1 Retail chains market, 2021-2033 (USD Billion)
5.7.2 Supermarket Pharmacies
5.7.2.1 Supermarket pharmacies market, 2021-2033 (USD Billion)
5.7.3 Health System / Hospital Pharmacy
5.7.3.1 Health system / Hospital pharmacy market, 2021-2033 (USD Billion)
5.7.4 Independent Pharmacies
5.7.4.1 Independent pharmacies market, 2021-2033 (USD Billion)
5.7.5 Mail-Order Pharmacies
5.7.5.1 Mail-order pharmacy market, 2021-2033 (USD Billion)
5.7.6 Specialty / Central Fill Pharmacies
5.7.6.1 Specialty / central fill pharmacies market, 2021-2033 (USD Billion)
5.7.7 Long-Term Care And Defense-Related Pharmacies
5.7.7.1 Long-term care and defense-related pharmacies market, 2021-2033 (USD Billion)
5.7.8 Epharmacy
5.7.8.1 ePharmacy market, 2021-2033 (USD Billion)
5.7.9 Others
5.7.9.1 Others market, 2021-2033 (USD Billion)
Chapter 6. U.S. Pharmacy Market Competitive Analysis
6.1 Company Categorization
6.2 Estimated Company Market Share Analysis, 2024
6.2.1 CVS Pharmacy
6.2.1.1 Company Overview
6.2.1.2 Financial Performance
6.2.1.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.1.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.1.2.3 Balance sheet health metrics (2024)
6.2.1.3 Volumes & Operations
6.2.1.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.1.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.1.3.3 % of prescriptions fulfilled by catchment areas (2024)
6.2.1.4 Value Chain Position
6.2.1.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.1.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.1.5 Central Fulfillment (if used/planned)
6.2.1.5.1 Strategy
6.2.1.5.2 Requirements
6.2.1.5.3 Technology provider(s) and hardware/automation
6.2.1.5.4 Partnerships
6.2.1.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.2 Walgreens Boots Alliance, Inc.
6.2.2.1 Company Overview
6.2.2.2 Financial Performance
6.2.2.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.2.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.2.2.3 Balance sheet health metrics (2024)
6.2.2.3 Volumes & Operations
6.2.2.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.2.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.2.3.3 % of prescriptions fulfilled by catchment areas (2024)
6.2.2.4 Value Chain Position
6.2.2.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.2.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.2.5 Central Fulfillment (if used/planned)
6.2.2.5.1 Strategy
6.2.2.5.2 Requirements
6.2.2.5.3 Technology provider(s) and hardware/automation
6.2.2.5.4 Partnerships
6.2.2.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.3 Scriptco Pharmacy
6.2.3.1 Company Overview
6.2.3.2 Financial Performance
6.2.3.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.3.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.3.2.3 Balance sheet health metrics (2024)
6.2.3.3 Volumes & Operations
6.2.3.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.3.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.3.4 Value Chain Position
6.2.3.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.3.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.3.5 Central Fulfillment (if used/planned)
6.2.3.5.1 Strategy
6.2.3.5.2 Requirements
6.2.3.5.3 Technology provider(s) and hardware/automation
6.2.3.5.4 Partnerships
6.2.3.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.4 Walmart Pharmacy
6.2.4.1 Company Overview
6.2.4.2 Financial Performance
6.2.4.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.4.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.4.2.3 Balance sheet health metrics (2024)
6.2.4.3 Volumes & Operations
6.2.4.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.4.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.4.3.3 % of prescriptions fulfilled by catchment areas (2024)
6.2.4.4 Value Chain Position
6.2.4.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.4.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.4.5 Central Fulfillment (if used/planned)
6.2.4.5.1 Strategy
6.2.4.5.2 Requirements
6.2.4.5.3 Technology provider(s) and hardware/automation
6.2.4.5.4 Partnerships
6.2.4.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.5 Avita Pharmacy
6.2.5.1 Company Overview
6.2.5.2 Financial Performance
6.2.5.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.5.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.5.2.3 Balance sheet health metrics (2024)
6.2.5.3 Volumes & Operations
6.2.5.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.5.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.5.4 Value Chain Position
6.2.5.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.5.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.5.5 Central Fulfillment (if used/planned)
6.2.5.5.1 Strategy
6.2.5.5.2 Requirements
6.2.5.5.3 Technology provider(s) and hardware/automation
6.2.5.5.4 Partnerships
6.2.5.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.6 The Kroger Co.
6.2.6.1 Company Overview
6.2.6.2 Financial Performance
6.2.6.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.6.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.6.2.3 Balance sheet health metrics (2024)
6.2.6.3 Volumes & Operations
6.2.6.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.6.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.6.3.3 % of prescriptions fulfilled by catchment areas (2024)
6.2.6.4 Value Chain Position
6.2.6.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.6.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.6.5 Central Fulfillment (if used/planned)
6.2.6.5.1 Strategy
6.2.6.5.2 Requirements
6.2.6.5.3 Technology provider(s) and hardware/automation
6.2.6.5.4 Partnerships
6.2.6.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.7 Albertsons Companies, Inc.
6.2.7.1 Company Overview
6.2.7.2 Financial Performance
6.2.7.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.7.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.7.2.3 Balance sheet health metrics (2024)
6.2.7.3 Volumes & Operations
6.2.7.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.7.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.7.3.3 % of prescriptions fulfilled by catchment areas (2024)
6.2.7.4 Value Chain Position
6.2.7.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.7.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.7.5 Central Fulfillment (if used/planned)
6.2.7.5.1 Strategy
6.2.7.5.2 Requirements
6.2.7.5.3 Technology provider(s) and hardware/automation
6.2.7.5.4 Partnerships
6.2.7.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.8 Costco Wholesale Corporation.
6.2.8.1 Company Overview
6.2.8.2 Financial Performance
6.2.8.2.1 Revenue (pharmacy-only where available/estimable), 2024-2029 (USD Million)
6.2.8.2.2 EBITDA (%) & EBITDA Margin (2024)
6.2.8.2.3 Balance sheet health metrics (2024)
6.2.8.3 Volumes & Operations
6.2.8.3.1 Estimated prescription volumes; 2024-2029 (Million)
6.2.8.3.2 % of prescriptions fulfilled via central fill (2024)
6.2.8.3.3 % of prescriptions fulfilled by catchment areas (2024)
6.2.8.4 Value Chain Position
6.2.8.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.8.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.8.5 Central Fulfillment (if used/planned)
6.2.8.5.1 Strategy
6.2.8.5.2 Requirements
6.2.8.5.3 Technology provider(s) and hardware/automation
6.2.8.5.4 Partnerships
6.2.8.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
6.2.9 Sam's West, Inc.
6.2.9.1 Company Overview
6.2.9.2 Value Chain Position
6.2.9.2.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
6.2.9.2.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
6.2.9.3 Central Fulfillment (if used/planned)
6.2.9.3.1 Strategy
6.2.9.3.2 Requirements
6.2.9.3.3 Technology provider(s) and hardware/automation
6.2.9.3.4 Partnerships
6.2.9.4 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 Specialty Drug Expenditures, 2016-2021
Table 4 U.S. Pharmacy Market Revenue Estimates and Forecast, By Product Type, 2021-2033 (USD Billion)
Table 5 U.S. Pharmacy Market Revenue Estimates and Forecast, By Type, 2021-2033 (USD Billion)
Table 6 U.S. Pharmacy Market: Estimated Number of Pharmacies, By Type, 2021-2033 (Unit)
Table 7 U.S. Pharmacy Market: Estimated Prescription Volume, By Type, 2021-2033 (Million)
Table 8 U.S. Pharmacy Market Revenue Estimates and Forecast, By Ownership, 2021-2033 (USD Billion)
Table 9 U.S. Pharmacy Market: Estimated Prescription Volume, By Catchment Area, 2024 (%)
Table 10 U.S. Pharmacy Market: Estimated Prescription Volume, By Filled Prescriptions (TRX), 2024 (%)
List of Figures
Figure 1 U.S. Pharmacy Market Segmentation
Figure 2 Market Research Process
Figure 3 Information Procurement
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Value-Chain-Based Sizing & Forecasting
Figure 7 Market Formulation & Validation
Figure 8 Market Snapshot
Figure 9 Segment Outlook-I
Figure 10 Segment Outlook-II
Figure 11 Competitive Scenario
Figure 12 U.S. Pharmacy Market: Parent Market Outlook
Figure 13 U.S. Pharmacy Market: Ancillary/Related Market Outlook
Figure 14 U.S. Pharmacy Market Dynamics
Figure 15 Market Driver Relevance Analysis (Current & Future Impact)
Figure 16 Estimated New Cancer Cases, 2024
Figure 17 Estimated US Prevalence of Stroke, 2018-2030
Figure 18 Estimated US Prevalence of Prostate Cancer, 2018-2030
Figure 19 Estimated US Prevalence of Kidney Cancer, 2018-2030
Figure 20 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 21 Number of Pharmacy Degrees Conferred 2018-2023 By Gender
Figure 22 U.S. Pharmacy Market: Porter’s Five Forces Analysis
Figure 23 U.S. Pharmacy Market: PESTLE Analysis
Figure 24 U.S. Pharmacy Market: Product Type Segment Dashboard
Figure 25 U.S. Pharmacy Market: Product Type Market Share Analysis, 2024 & 2033
Figure 26 Prescription Market, 2021-2033 (USD Billion)
Figure 27 OTC Market, 2021-2033 (USD Billion)
Figure 28 U.S. Pharmacy Market: Type Segment Dashboard
Figure 29 U.S. Pharmacy Market: Type Market Share Analysis, 2024 & 2033
Figure 30 Retail Pharmacy Market, 2021-2033 (USD Billion)
Figure 31 Supermarket Pharmacies Market, 2021-2033 (USD Billion)
Figure 32 Health System / Hospital Pharmacy Market, 2021-2033 (USD Billion)
Figure 33 Independent Pharmacies Market, 2021-2033 (USD Billion)
Figure 34 Mail-Order Pharmacy Market, 2021-2033 (USD Billion)
Figure 35 Specialty / Central Fill Pharmacies Market, 2021-2033 (USD Billion)
Figure 36 Long-Term Care and Defense-Related Pharmacies Market, 2021-2033 (USD Billion)
Figure 37 E-pharmacy Market, 2021-2033 (USD Billion)
Figure 38 Others Market, 2021-2033 (USD Billion)
Figure 39 U.S. Pharmacy Market: Ownership Segment Dashboard
Figure 40 U.S. Pharmacy Market: Ownership Market Share Analysis, 2024 & 2033
Figure 41 Chain Pharmacy Market, 2021-2033 (USD Billion)
Figure 42 Independent Pharmacy Market, 2021-2033 (USD Billion)
Figure 43 Key Company Categorization
Figure 44 Estimated Company Market Share Analysis, 2024
